High frequency of activated K-ras codon 15 mutant in colorectal carcinomas from Taiwanese patients

International Journal of Cancer

Volumn 107, Issue 3, 2003, Pages 387-393

  Wang, Jaw Yuan ^a,b   Hsieh, Jan Sing ^a   Chen, Fang Ming ^a,b   Yeh, Ching Sheng ^b   Alexandersen, Ketil ^b   Huang, Tsung Jen ^a   Chen, David C P ^c   Lin, Shiu Ru ^b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c Asia Hepato Gene Co Ltd   (Taiwan)

Author keywords

Activated K ras; Codon 15; Colorectal carcinoma; Taiwan

Indexed keywords

DNA; GUANOSINE TRIPHOSPHATASE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CODON; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TAIWAN;

ADULT; AGED; AGED, 80 AND OVER; CODON; COLORECTAL NEOPLASMS; FEMALE; GENES, RAS; GTP PHOSPHOHYDROLASES; GTPASE-ACTIVATING PROTEINS; HUMANS; MALE; MIDDLE AGED; MUTATION;

EID: 0142090694     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11417     Document Type: Article

References (42)

1. Winawer SJ, Schottenfeld D, Flehinger BJ. Colorectal cancer screening. J Natl Cancer Inst 1991;83:243-53.
2. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. [published erratum appears in N Engl J Med 1993;329:672]. N Engl J Med 1993;328:1365-71.
3. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. [published erratum appears in N Engl J Med 1993;329:672]. N Engl J Med 1993;328:1365-71.
4. Byers T, Levin B, Rothenberger D, Dodd GD, Smith RA. American Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: update 1997. American Cancer Society Detection and Treatment Advisory Group on Colorectal Cancer. CA Cancer J Clin 1997;47:154-60.
5. Department of Health. Health and Vital Statistics, 1999. Taipei: Department of Health; 2000. p71-85.
6. Steele G Jr. Accomplishment and promise in the understanding and treatment of colorectal cancer. Lancet 1993;342:1092-6.
7. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994;330:1136-42.
8. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319:525-32.
9. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
10. Barbacid M. Ras gene. Ann Rev Biochem 1987;56:779-827.
11. Losi L, Benhattar J, Costa J. Stability of K-ras mutations throughout the natural history of human colorectal cancer. Eur J Cancer 1992; 28A:1115-20.
12. Suchy B, Zietz C, Rabes HM. K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis. Int J Cancer 1992;52:30-3.
13. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, Vogelstein B. Prevalence of K-ras mutations in human colorectal cancer. Nature 1987;327:293-7.
14. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987;327:298-303.
15. Shaw P, Tardy S, Benito E, Obrador A, Costa J. Occurrence of Ki-ras and p53 mutations in primary colorectal tumors. Oncogene 1991;6: 2121-8.
16. Finkelstein SD, Sayegh R, Christensen S, Swalsky PA. Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer 1993;71:3827-38.
17. Downeard J. Control of ras activation. Cancer Surv 1996;27:87-100.
18. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. New York: Cold Spring Harbor Laboratory; 1989. p 6.22-6.34.
19. Lin SR, Tsai JH, Yang YC, Lee SC. Mutations of K-ras oncogene in human adrenal tumours in Taiwan. Br J Cancer 1998;77:1060-5.
20. Lin SR, Hsu CH, Tsai JH, Wang JY, Hsieh TJ, Wu CH. Decreased GTPase activity of K-ras mutants deriving from human functional adrenocortical tumours. Br J Cancer 2000;82:1035-40.
21. Gross M, Sweet RW, Sathe G, Yokoyama S, Fasano O, Goldfarb M, Wigler M, Rosenberg M. Purification and characterization of human H-Ras proteins expressed in Escherichia coli. Mol Cell Biol 1985;5: 1015-24.
22. Lim HH, Michael GJ, Smith P, Lim L, Hall C. Developmental regulation and neuronal expression of the mRNA of rat n-chimaerin, a p21rac GAP:cDNA sequence. Biochem J 1992;287:415-22.
23. Astler VB, Coller FA. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 1954;139:846-51.
24. Bos JL. The ras gene family and human carcinogenesis. Mutat Res 1988;195:225-71.
25. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
26. Gibbs JB, Sigal IS, Scolnick EM. Biochemical properties of normal and oncogenic ras p21. Trends Biochem Sci 1985;10:350-3.
27. Hall A. The cellular functions of small GTP-binding proteins. Science 1990;249:635-40.
28. Suzuki Y, Orita M, Shiraishi M, Hayashi K, Sekiya T. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1990;5:1037-43.
29. Hongyo T, Buzard GS, Palli D, Weghorst CM, Amorosi A, Galli M, Caporaso NE, Fraumeni JF Jr, Rice JM. Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. Cancer Res 1995;55:2665-72.
30. McLellan EA, Owen RA, Stepniewska KA, Sheffield JP, Lemoine NR. High frequency of K-ras mutations in sporadic colorectal adenomas. Gut 1993;34:392-6.
31. Finkelstein SD, Sayegh R, Bakker A, Swalsky P. Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg 1993;128:526-31.
32. Chiang JM, Chou YH, Chou TB. K-ras codon 12 mutation determines the polypoid growth of colorectal cancer. Cancer Res 1998;58:3289-93.
33. Tsukuda K, Tanino M, Soga H, Shimizu N, Shimizu K. A novel activating mutation of the K-ras gene in human primary colon adenocarcinoma. Biochem Biophys Res Commun 2000;278:653-8.
34. Powers S, O'Neill K, Wigler M. Dominant yeast and mammalian RAS mutants that interfere with the CDC25-dependent activation of wild-type RAS in Saccharomyces cerevisiae. Mol Cell Biol 1989;9: 390-5.
35. Wu CH, Lee SC, Chiu HH, Yang YC, Lian ST, Shin SJ, Lin SR. Morphologic change and elevation of cortisol secretion in cultured human normal adrenocortical cells caused by mutant p21K-ras protein. DNA Cell Biol 2002;21:21-9.
36. Shirasawa S. Furuse M. Yokoyama N. Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993;260:85-8.
37. D'Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE, Cox JD, Ha SI, Belka GK, Golant A, Cardiff RD, Chodosh LA. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 2001;7: 235-9.
38. Bardeesy N, Bastian BC, Hezel A, Pinkel D, DePinho RA, Chin L. Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol Cell Biol 2001;21:2144-53.
39. Hayashi N, Sugai S, Ito I, Nakamori S, Ogawa M, Nakamura Y. Ethnic difference in the pattern of K-ras oncogene mutations in human colorectal cancers. Hum Mutat 1996;8:258-61.
40. Capellá G, Cronauer-Mitra S, Pienado MA, Perucho M. Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Environ Health Perspect 1991;93:125-31.
41. Brown K, Buchmann A, Balmain A. Carcinogen-induced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumor progression. Proc Natl Acad Sci USA 1990;87:538-42.
42. Wang JY, Lian ST, Chen YF, Yang YC, Chen LT, Lee KT, Huang TJ, Lin SR. Unique K-ras mutational pattern in pancreatic adenocarcinoma from Taiwanese patients. Cancer Lett 2002;180:153-8.